COBAS® AMPLIPREP/COBAS® TAQMAN® CMV TEST (CAP/CTM CMV TEST)

Cytomegalovirus (cmv) Dna Quantitative Assay

FDA Premarket Approval P110037

This medical device has supplements. The device description/function or indication may have changed. Be sure to look at the supplements to get an up-to-date information on device changes. The labeling included below is the version at time of approval of the original pma or panel track supplement and may not represent the most recent labeling.

Pre-market Approval Supplement Details

Approval for the cobas ampliprep/cobas taqman cmv test. This device is indicated for: the cobas ampliprep/cobas taqman cmv test is an in vitro nucleic acid amplification test for the quantitative measurement of cytomegalovirus (cmv) dna in human edta plasma using the cobas ampliprep instrument for automated specimenprocessing and the cobas taqman analyzer or the cobas taqman 48 analyzer for automated amplification and detection. The cobas ampliprep/ cobas taqman cmv test is intended for use as an aid in the management of solid-organ transplant patients who are undergoing anti-cmv therapy. In this population serial dna measurements can be used to assess virological response to antiviral treatment. The results from the cobas ampliprep/cobas taqman cmvtest must be interpreted within the context of all relevant clinical and laboratory findings. The cobas ampliprep/cobas taqman cmv test is not intended for use as a screening test for the presence of cmv dna in blood or blood products.

DeviceCOBAS® AMPLIPREP/COBAS® TAQMAN® CMV TEST (CAP/CTM CMV TEST)
Classification NameCytomegalovirus (cmv) Dna Quantitative Assay
Generic NameCytomegalovirus (cmv) Dna Quantitative Assay
ApplicantRoche Molecular Systems, Inc.
Date Received2011-10-24
Decision Date2012-07-05
Notice Date2012-07-11
PMAP110037
SupplementS
Product CodePAB
Docket Number12M-0713
Advisory CommitteeMicrobiology
Expedited ReviewNo
Combination Product No
Applicant Address Roche Molecular Systems, Inc. 4300 Hacienda Drive pleasanton, CA 94588-2722
Summary:Summary of Safety and Effectiveness
Labeling: Labeling
Approval Order: Approval Order

Supplemental Filings

Supplement NumberDateSupplement Type
P110037Original Filing
S057 2022-10-21 30-day Notice
S056 2021-06-14 30-day Notice
S055 2021-02-23 30-day Notice
S054 2020-07-27 30-day Notice
S053 2020-04-17 30-day Notice
S052 2020-01-23 30-day Notice
S051 2019-10-08 30-day Notice
S050 2019-09-20 30-day Notice
S049 2019-08-16 30-day Notice
S048 2019-07-15 Special (immediate Track)
S047 2019-04-24 30-day Notice
S046 2019-04-10 30-day Notice
S045 2019-03-20 30-day Notice
S044 2018-12-14 30-day Notice
S043 2018-11-13 30-day Notice
S042 2018-11-09 30-day Notice
S041 2018-08-21 30-day Notice
S040 2018-07-27 30-day Notice
S039 2018-06-29 30-day Notice
S038 2018-06-08 30-day Notice
S037 2018-06-04 30-day Notice
S036 2018-04-16 30-day Notice
S035 2018-04-16 30-day Notice
S034 2018-03-01 30-day Notice
S033 2017-11-14 30-day Notice
S032 2017-09-26 30-day Notice
S031 2017-07-14 30-day Notice
S030 2017-07-14 30-day Notice
S029 2016-09-22 30-day Notice
S028 2016-07-19 30-day Notice
S027 2016-07-08 30-day Notice
S026 2016-04-18 30-day Notice
S025 2016-04-07 30-day Notice
S024 2015-11-17 Real-time Process
S023 2015-10-22 Normal 180 Day Track
S022 2015-06-24 30-day Notice
S021 2015-04-09 30-day Notice
S020 2015-03-13 30-day Notice
S019 2015-02-25 Real-time Process
S018 2014-12-19 30-day Notice
S017 2014-12-19 30-day Notice
S016 2014-12-16 Real-time Process
S015 2014-03-31 30-day Notice
S014 2014-03-18 30-day Notice
S013 2014-02-18 30-day Notice
S012 2013-10-30 30-day Notice
S011 2013-09-09 30-day Notice
S010 2013-09-09 30-day Notice
S009 2013-08-14 30-day Notice
S008 2013-08-09 30-day Notice
S007 2013-07-26 30-day Notice
S006 2013-05-09 30-day Notice
S005 2013-02-19 Special (immediate Track)
S004 2012-11-16 Real-time Process
S003 2012-11-02 Real-time Process
S002 2012-08-15 30-day Notice
S001 2012-08-07 Real-time Process

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.